Local view for "http://wifo5-04.informatik.uni-mannheim.de/drugbank/resource/drugs/DB05773"

Predicate	Value (sorted: none)
drugbank:interactsWith	drug:Tofacitinib
owl:sameAs	drug:Tacrolimus
drugbank:interactsWith	drug:Belimumab
rdfs:label	"ado-trastuzumab emtansine"
rdf:type	drugbank:drugs
owl:sameAs	drug:Tofacitinib
owl:sameAs	drug:Pimecrolimus
owl:sameAs	drug:Clozapine
drugbank:drugCategory	drugcategory:Tubulin Modulators
owl:sameAs	drug:Natalizumab
drugbank:interactsWith	drug:Natalizumab
owl:sameAs	drug:Belimumab
owl:sameAs	drug:Phenytoin
drugbank:drugCategory	drugcategory:Monoclonal antibodies
drugbank:interactsWith	drug:Tacrolimus
drugbank:description	"Ado-trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) as an investigational drug, is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Ado-trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that ado-trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity. "
drugbank:interactsWith	drug:Clozapine
drugbank:drugCategory	drugcategory:Antineoplastic Agents
drugbank:interactsWith	drug:Pimecrolimus
drugbank:interactsWith	drug:Phenytoin

All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines3/drugbank_small.nt

The resource appears as object in 14 triples

Context graph